

## Review article: the role of butyrate on colonic function

H. M. HAMER<sup>\*,†</sup>, D. JONKERS<sup>\*,†</sup>, K. VENEMA<sup>\*,‡</sup>, S. VANHOUTVIN<sup>\*,†</sup>, F. J. TROOST<sup>\*,†</sup> & R.-J. BRUMMER<sup>\*,†</sup>

<sup>\*</sup>T1 Food and Nutrition, Wageningen;  
<sup>†</sup>Department of Internal Medicine,  
Division of Gastroenterology-Hepatology,  
Nutrim, Maastricht University,  
Maastricht; <sup>‡</sup>Department of  
Biosciences, TNO Quality of Life,  
Zeist, the Netherlands

Correspondence to:

Dr H. M. Hamer, Division of  
Gastroenterology-Hepatology,  
University of Maastricht, PO Box 616,  
6200 MD Maastricht, the Netherlands.  
E-mail: h.hamer@intmed.unimaas.nl

### Publication data

Submitted 11 July 2007  
First decision 21 July 2007  
Resubmitted 5 October 2007  
Second decision 12 October 2007  
Accepted 22 October 2007

## SUMMARY

### Background

Butyrate, a short-chain fatty acid, is a main end-product of intestinal microbial fermentation of mainly dietary fibre. Butyrate is an important energy source for intestinal epithelial cells and plays a role in the maintenance of colonic homeostasis.

### Aim

To provide an overview on the present knowledge of the bioactivity of butyrate, emphasizing effects and possible mechanisms of action in relation to human colonic function.

### Methods

A PubMed search was performed to select relevant publications using the search terms: 'butyrate, short-chain fatty acid, fibre, colon, inflammation, carcinogenesis, barrier, oxidative stress, permeability and satiety'.

### Results

Butyrate exerts potent effects on a variety of colonic mucosal functions such as inhibition of inflammation and carcinogenesis, reinforcing various components of the colonic defence barrier and decreasing oxidative stress. In addition, butyrate may promote satiety. Two important mechanisms include the inhibition of nuclear factor kappa B activation and histone deacetylation. However, the observed effects of butyrate largely depend on concentrations and models used and human data are still limited.

### Conclusion

Although most studies point towards beneficial effects of butyrate, more human *in vivo* studies are needed to contribute to our current understanding of butyrate-mediated effects on colonic function in health and disease.

*Aliment Pharmacol Ther* 27, 104–119

## INTRODUCTION

Short-chain fatty acids (SCFAs), primarily acetate, propionate and butyrate, are organic acids produced within the intestinal lumen by bacterial fermentation of mainly undigested dietary carbohydrates, but also in a minor part by dietary and endogenous proteins, such as mucous, and sloughed epithelial cells.<sup>1</sup> Most micro-organisms prefer to ferment carbohydrate over protein and therefore saccharolytic bacterial fermentation occurs predominantly in the proximal colon, while proteolytic fermentation mainly takes place in the distal colon where fermentable carbohydrates are depleted. The latter is considered less favourable for the host because potentially toxic metabolites are formed such as ammonia, sulphur-containing compounds, indoles and phenols. As this distal part of the colon is the predominant location of several gastrointestinal disorders, such as ulcerative colitis (UC) and colon cancer, it could be hypothesized that the production of these toxic metabolites and a lower availability of SCFAs are involved in the pathogenesis of these diseases.<sup>2, 3</sup>

The production of SCFAs allows the salvage of energy mainly from carbon sources as dietary fibre that is not digested in the small intestine. It has been estimated that SCFAs can contribute to about 5–15% of the total caloric requirements of humans.<sup>4</sup> An important SCFA produced is butyrate that besides being an energy source for the epithelial cells also influences a wide array of cellular functions affecting colonic health. As such, butyrate may have an anticarcinogenic and anti-inflammatory potential, affect the intestinal barrier and play a role in satiety and oxidative stress.

Because of this important role of butyrate and the rather low consumption of fermentable dietary fibre in today's Western diet, food manufacturers are interested in adding fibre sources to foods and beverages that rely on slow bacterial fermentation to increase distal colonic butyrate concentrations. In medical application, butyrate has also been proposed as a potential therapeutic agent for colonic inflammation.<sup>5</sup> In a book by Cummings *et al.* published in 1995,<sup>6</sup> the effects of butyrate have been nicely reviewed, but the reported effects have often been based on *in vitro* and animal data. During the last decade, additional human (intervention) studies were published and knowledge on possible mechanisms of action is improving. This review summarizes the present knowledge on the



Figure 1. Different domains that may be affected by butyrate produced in the colonic lumen.

bioactivity of butyrate, emphasizing effects and possible mechanisms of action in relation to human colonic function (Figure 1).

## Production and absorption of SCFAs

Total and relative molar concentrations of the main SCFAs, acetate, propionate and butyrate produced in the human intestine, depend on the site of fermentation, diet and composition of the intestinal microbiota.<sup>7</sup> Absolute concentrations of butyrate in human faeces were found to range from 11 to 25 mM,<sup>8, 9</sup> and molar ratios of acetate to propionate to butyrate varied between 48:29:23 and 70:15:15, respectively, with mean values of approximately 60:20:20.<sup>1, 9</sup> However, the *in situ* production of total colonic SCFAs is difficult to determine because more than 95% of the SCFAs are rapidly absorbed and metabolized by the host.<sup>1</sup> Subsequently, faecal concentrations of SCFAs are not necessarily representative of those in the more proximal colon and can also be affected by intestinal transit time.<sup>10</sup> Probably for these reasons, various studies were not able to show effects of different fermentable substrates on faecal SCFA concentrations.<sup>11, 12</sup>

Because of the difficult accessibility of the human colon, estimates of luminal SCFA concentrations are based on analyses in human gut contents of sudden-death victims<sup>13, 14</sup> and stomal effluent of patients with transverse or sigmoid colostomy.<sup>15</sup> In autopsy samples, total SCFA concentrations varied from 137 to 197 mmol/kg chyme in the caecum to 86 to 97 mmol/kg chyme in the descending colon.<sup>13, 14</sup> In transverse colostomy samples SCFA concentrations were high (1400 mol/kg dry matter) compared to those in sigmoid colostomy samples (550 mol/kg dry matter), which were similar to the concentrations in faeces from controls.<sup>15</sup> In line with the SCFA concentrations, the pH value is the lowest in the proximal colon (pH  $\approx$  5.6) and increases towards the distal colon (pH  $\approx$  6.3).<sup>14</sup>

As SCFAs are weak acids ( $pK_a \approx 4.8$ ), more than 90% exist in the anionic, dissociated form in the colonic lumen.<sup>16</sup> Several different mechanisms of uptake of SCFAs across the apical membrane of the colonocytes have been proposed, including diffusion of the undissociated (lipid soluble) form,<sup>16</sup> SCFA/ $HCO_3^-$  exchange<sup>17, 18</sup> and active transport of the dissociated form by SCFA-transporters. Two SCFA-transporters have been reported: the monocarboxylate transporter isoform 1 (MCT1), which is coupled to a transmembrane  $H^+$ -gradient<sup>19</sup> and SLC5A8, which is a  $Na^+$ -coupled co-transporter and is also denoted sodium-coupled monocarboxylate transporter (SMCT1).<sup>20</sup> SCFAs, with butyrate being the most potent one, hereby stimulate the absorption of sodium and water<sup>21</sup> and can be considered as antidiarrhoeal agents.<sup>22</sup> The transport mechanisms involved in basolateral transport of SCFAs are still unclear.

The majority of the absorbed butyrate is metabolized by the colonic epithelium, resulting in low concentrations of butyrate in portal blood. Human portal butyrate concentrations ranged from 1.3 to 14.4  $\mu M$  in patients during gall-bladder surgery<sup>23</sup> and from 14 to 64  $\mu M$  in sudden death victims.<sup>14</sup> Most likely, the liver subsequently extracts the majority of the remaining butyrate, resulting in even lower venous systemic serum butyrate concentrations ranging from 0.5 to 3.3  $\mu M$ .<sup>24–27</sup> Serum concentrations of propionate and acetate in peripheral blood have been shown to range from 3.8 to 5.4 and from 98 to 143  $\mu M$ , respectively.<sup>24–27</sup>

### Delivery of butyrate

An important source of butyrate is colonic fermentation of dietary fibre. The rate and amount of butyrate being produced along the colonic lumen during dietary fibre supplementation depends on its chemical structure, such as solubility and degree of polymerization. Insoluble fibres (e.g. cellulose and lignin) have a rather low fermentability, but are associated with increased faecal mass and decreased colonic transit time. Soluble fibres are highly fermentable and hence generate greater quantities of SCFAs in the colon.<sup>28</sup> Fibres with a higher degree of polymerization are more resistant to saccharolytic fermentation resulting in prolonged fermentation, expanding towards the distal colon.<sup>29</sup> Examples of fermentable dietary and chemically modified fibres that are associated with a higher production of SCFAs either *in vitro* or *in vivo*

are oligofructose,<sup>30</sup> inulin,<sup>31</sup> psyllium,<sup>32</sup> germinated barley foodstuff,<sup>33</sup> hydrolysed guar gum,<sup>34</sup> oat bran,<sup>9, 35</sup> corn starch,<sup>12</sup> isomalt,<sup>11</sup> gluconic acid<sup>36</sup> and butyrylated starch.<sup>37</sup> Although the beneficial effects of these fibres are often attributed to the increased butyrate production, these soluble fibres can also affect other intestinal characteristics influencing intestinal health, such as increased faecal bulk, shortened colonic transit time, changes in the composition of the gut microbiota, lowered intraluminal pH and changed bile acid profiles.<sup>38</sup>

Apart from dietary fibres, also other ingested substrates can contribute to an increase in the colonic butyrate concentrations by different mechanisms. An example is the oligosaccharide acarbose that increases the amount of starch entering the colon by acting as an  $\alpha$ -glucosidase inhibitor.<sup>8, 25</sup> In addition, tributyrin, a triglyceride containing three butyrate molecules esterified to glycerol, augments butyrate concentrations after hydrolysis by pancreatic and gastric lipases.<sup>39</sup> Also, butyrate tablets coated with a slow release pH-dependent coating releasing butyrate in the distal ileum and proximal colon can be used.<sup>40, 41</sup> However, these tablets may not always disintegrate and release their content at the intended location because of interindividual differences in intracolonic pH and transit time.<sup>42</sup> Finally, consumption of several types of butyrate-producing probiotic bacterial strains, such as *Butyrivibrio fibrisolvens*<sup>43</sup> and *Clostridium butyricum*,<sup>33, 44</sup> has been studied in animal models.

Besides using oral substrates to increase colonic butyrate concentrations, a number of clinical intervention studies in patients with distal colonic inflammation have applied rectal enemas to deliver butyrate to the distal colon.<sup>45</sup> However, use of enemas is often hampered by a low compliance rate and a short and discontinuous exposure of the colon mucosa to butyrate.<sup>46</sup> These studies will be discussed in a later section.

### BUTYRATE AND COLON CARCINOGENESIS

One of the proposed beneficial effects of butyrate on human intestinal health is the prevention and inhibition of colon carcinogenesis. Although epidemiological studies are still inconclusive, most of these studies showed an inverse relationship between dietary fibre intake and the incidence of colorectal cancer.<sup>40, 41, 47–53</sup> Several studies hypothesized that increased colonic concentrations of butyrate are an important mediator in the

observed protective effect of fermentable dietary fibre.<sup>32, 47, 54, 55</sup> In many of these studies, however, the physiological properties of the ingested dietary fibres have not been considered.<sup>56</sup> A role for butyrate in the development of colon cancer has recently been supported by the downregulation of butyrate transporters (MCT1 and SMCT1) in human colon cancer tissue,<sup>57, 58</sup> which results in a reduced uptake and metabolism of butyrate in the colonocytes. In addition, the SMCT1 activity was positively correlated with the disease-free survival.<sup>59</sup> Moreover, a lower butyrate to acetate ratio has been found in luminal samples of patients with adenomatous polyps or colon cancer vs. healthy controls.<sup>60</sup> Although several well-designed animal models have demonstrated a protective effect of butyrate on colorectal carcinogenesis,<sup>55, 61–67</sup> direct evidence for a protective effect of butyrate on carcinogenesis in humans is still lacking.

Knowledge and hypotheses concerning the mechanistic effects of butyrate on carcinogenesis are mainly based on *in vitro* cell systems. *In vitro* exposure of many tumour cell lines to butyrate leads to anticarcinogenic effects by induction of apoptosis,<sup>68, 69</sup> inhibition of proliferation<sup>70, 71</sup> and promotion of a more differentiated phenotype.<sup>70, 71</sup>

In contrast to these relatively consistent findings in tumour cell lines, the observed effects of butyrate on noncarcinogenic cells are more diverse and do not always point in the same direction as in tumour cells.<sup>70, 72</sup> Also, some data from human (intervention) studies are available, which focus predominantly on the effect of SCFAs on colonocytic proliferation. Treatment with SCFA enemas for 2 weeks increased rectal proliferative activity in patients with a closed atrophic rectum that was deprived of its natural SCFA source.<sup>73</sup> In a study by Scheppach *et al.*,<sup>74</sup> human colonic biopsies were exposed to butyrate *ex vivo* for 4 h, which revealed that butyrate increased the proliferation rate at the basal 60% area of the crypt. It has been proposed that butyrate stimulates the physiological pattern of proliferation that is normally confined to the basal crypt.<sup>75</sup> Expansion of the proliferative zone towards the crypt surface has been considered a biomarker of increased susceptibility to cancer formation.<sup>76</sup> In colonic biopsies from patients with UC, expansion of the proliferative zone has been shown and has been found to be independent of the degree of inflammation.<sup>77</sup> Treatment with butyrate enemas for 2 weeks decreased the proliferation rate in the upper part of the crypt in colonic biopsies of active

UC patients, resulting in values comparable to those of healthy control subjects.<sup>45</sup>

These apparent contradicting effects of butyrate found in normal colonocytes and in neoplastic cells are often referred to as the 'butyrate paradox'.<sup>70</sup> There are several explanations for these contrasting effects. First, they may reflect the inherent differences of the cells, the cells' state of activation and their energy status. Furthermore, it may be the result of different concentrations of butyrate and the different exposure times to butyrate used in these experiments. Finally, the ability of the cells to  $\beta$ -oxidize butyrate may influence their response to butyrate, as it can influence the rate of removal of butyrate from the cytoplasm and hence the availability of butyrate to exert its effects.<sup>78, 79</sup>

### Mechanisms of butyrate's anticarcinogenic effect

Although the exact underlying mechanisms of action have not yet been elucidated, the ability of butyrate to influence cell function is considered to be because of its regulation of gene expression, which is often attributed to its inhibition of histone deacetylase (HDAC).<sup>78, 80</sup> This results in hyperacetylation of histones and enhancement of the accessibility of transcription factors to nucleosomal DNA.<sup>69, 81, 82</sup> However, it is likely that butyrate has other intracellular targets, including hyperacetylation of nonhistone proteins, alteration of DNA methylation, selective inhibition of histone phosphorylation and modulation of intracellular kinase signalling.<sup>80</sup> This multiplicity of effects may underlie the ability of butyrate to modulate gene expression and have impact on key regulators of apoptosis and cell cycle as was demonstrated for cell cycle inhibitor p21<sup>69, 81</sup> and proapoptotic protein BAK.<sup>68, 83</sup> Interestingly, cancer cells appear to be more sensitive to the actions of HDAC inhibitors than nontransformed cells, but the mechanistic basis for this apparent selectivity is poorly understood.<sup>83</sup>

One of the effects also demonstrated in humans is the effect of butyrate on the plasminogen/plasmin system (PPS). Increases in tumour and serum levels of several components of the PPS are found to correlate with a more invasive tumour cell phenotype and a worse prognosis in patients with colon cancer.<sup>84</sup> *In vitro*<sup>85</sup> and *in vivo* studies<sup>86, 87</sup> have shown that butyrate is able to alter the balance of components of the PPS in a manner that favours net decreased plasminogen activator activity.

Other effects of butyrate studied in multiple colonic cancer cell lines include the enhancement of the activity of the detoxifying enzyme glutathione-S-transferase.<sup>88</sup> Furthermore, butyrate may have an inhibitory effect on tumour cell migration by inhibiting decay-accelerating factor (DAF) expression<sup>89</sup> and pro-metastatic metalloproteinase activation.<sup>90, 91</sup> Finally, it has also been suggested that butyrate inhibits tumour-induced angiogenesis through modulation of two angiogenesis-related proteins, vascular endothelial growth factor (VEGF) and hypoxia-inducible factor (HIF)-1 $\alpha$ .<sup>92</sup>

In conclusion, butyrate may have a protective role in the prevention and progression of colorectal carcinogenesis. However, the effects on apoptosis and proliferation appear to differ between normal and neoplastic tissue. The different models and concentrations being used may partly explain this paradox. Therefore, effects and mechanisms identified by *in vitro* models have to be confirmed in humans under physiological conditions.

## BUTYRATE AND INFLAMMATION

The intestinal epithelium, particularly in the colon, is permanently in close association with a myriad of microbes and their products. Therefore, the enterocytes must sense and respond appropriately to this potential immunological challenge of the luminal content. This leads to a normal physiological state of controlled low-grade inflammation.<sup>93</sup> However, mechanisms that allow individuals to tolerate commensal microbes, and thus limit the inflammatory response, are not yet completely understood. In some conditions, such as inflammatory bowel disease, this immunological control is thought to be disturbed.<sup>94</sup>

Several studies, both *in vitro* and *in vivo*, indicate that bacterial metabolites such as butyrate may affect the host immune response. As butyrate is known to be an important energy source for the colonic epithelium, it has been hypothesized that a lack of luminal SCFAs or the inability to oxidize butyrate leads to a nutritional deficiency of the colonic epithelium, causing mucosal atrophy in short term and 'nutritional colitis' in long term.<sup>95</sup> Possible changes in intestinal butyrate concentrations and/or oxidation of butyrate have been reported in diversion colitis and UC. Diversion colitis may occur as complication after a surgically diverted intestine (e.g. Hartmann's procedure), and is characterized by severely decreased luminal concentrations of

SCFAs of 0, 4 and 0.8 mM for acetate, propionate and butyrate, respectively, measured in the bypassed part of the rectosigmoid.<sup>96</sup> UC is an inflammatory bowel disease, characterized by alternating periods of flare ups and quiescent disease.<sup>97</sup> Increased<sup>95, 98</sup> as well as decreased<sup>99, 100</sup> faecal concentrations of butyrate have been reported in patients with active UC, but these were never as low as in diversion colitis.<sup>96</sup> In addition, a diminished capacity of the intestinal mucosa to oxidize butyrate has been reported in patients with active UC.<sup>101, 102</sup> In patients with inactive UC, however, a normal butyrate oxidation has been found *in vivo*,<sup>101, 103</sup> which suggests that abnormal butyrate oxidation is not a primary defect in colon mucosa of UC patients. A possible explanation for the decreased oxidation in UC patients was proposed by Nancey *et al.* who showed that butyrate oxidation could be reduced by TNF $\alpha$  at concentrations found in inflamed human mucosa.<sup>104</sup> It has also been reported that butyrate oxidation in colonocytes can be inhibited by hydrogen sulphide *in vitro*.<sup>105</sup> Increased luminal concentrations of sulphide as well as high numbers of sulphate-reducing bacteria have been reported in UC patients.<sup>105, 106</sup> However, evidence for hydrogen sulphide as a metabolic toxin in UC *in vivo* remains limited.<sup>105–108</sup>

## Intervention studies

Several animal studies have been performed to evaluate the effects of butyrate on inflammation and preventive as well as therapeutic effects have been reported.<sup>109–112</sup>

Human studies analysing the effects of SCFAs were performed in patients with colonic inflammation using rectal enemas containing SCFA mixtures or butyrate alone (Table 1).<sup>45, 46, 73, 96, 113–126</sup>

Most of these studies focussed on UC patients with moderate to active disease. Although some controlled studies with enemas containing butyrate or SCFA mixtures in UC patients did not find beneficial effects<sup>121</sup> or only trends towards clinical improvement,<sup>46, 118, 119</sup> various other studies revealed a significant improvement in clinical and inflammatory parameters.<sup>45, 115, 120, 124, 126</sup> Studies in patients with diversion colitis reported inconsistent results with regard to improvement in clinical symptoms and inflammatory parameters in response to administration of mixtures of SCFAs vs. placebo.<sup>96, 114</sup> Two other human intervention studies determined mucosal cell proliferation in patients

Table 1. Studies performed using butyrate and/or SCFA enemas in different patient groups

Patients	n	Enema treatment	Results	Reference
Active distal UC	10	100 mM butyrate and placebo 100 mL, pH = 7, b.d. for 2 weeks. Wash out: 2 weeks	Butyrate → stool frequency↓, blood discharge↓ and endoscopic and histological scores↓	45
	45	CS, 5-ASA or 130 mM SCFA (46:23:31*) 60 mL, pH = 7, b.d. for 6 weeks	SCFAs equally efficacious to CS or 5-ASA	120
	40	150 mM SCFA (53:20:27) vs. placebo 100 mL b.d. for 6 weeks	SCFAs → intestinal bleeding↓, urgency↓ and patient self-evaluation score↑	126
	47	130 mM SCFA (46:23:31) vs. 100 mM butyrate vs. placebo 60 mL, pH = 5.5, b.d. for 4–8 weeks	No differences between groups. Butyrate for 8 weeks → fewer colonic segments affected endoscopically	118
	38	80 mM butyrate vs. placebo 60 mL, pH = 7 for 6 weeks	No differences between butyrate and placebo treatment	121
	91	150 mM SCFA (53:20:27) vs. placebo 100 mL, pH = 7 b.d. for 6 weeks	SCFA enemas were not of therapeutic value	46
	35	130 mM SCFA (46:23:31) vs. 100 mM butyrate vs. placebo 60 mL, pH = 5.5, b.d. for 4–8 weeks	Butyrate → trend for reduced density of neutrophils in lamina propria. SCFA and butyrate → cell proliferation in upper crypt↓	119
	11	100 mM butyrate vs. placebo 60 mL, pH = 5.5 b.d. for 4–8 weeks	Butyrate → number of nuclear translocated NF-κB-positive macrophages↓, number of neutrophils↓ and Disease Activity Index↓	115
	51	5-ASA and saline vs. 5-ASA and 80 mM butyrate 80 mL b.d. for 6 weeks	5-ASA in combination with butyrate → more patients into remission, bowel movements↓, urgency↓ and patient's self-evaluation↑	124
	Diversion colitis	4	130 mM SCFA (46:23:31) vs. placebo 60 mL, pH = 7 b.d. for 2–60 weeks	SCFAs → clinical symptoms↓ and histological score↓
13		130 mM SCFA (46:23:31) vs. placebo 60 mL, pH = 7 b.d. for 2 weeks	No endoscopic or histological changes	114
After Hartmann's procedure	6	150 mM SCFA (58:27:15) 100 mL b.d. for 10–14 days	SCFAs had a trophic and vasodilatory effect	116
	8	150 mM SCFA (50:29:21) and placebo 100 mL, pH = 7.0 b.d. for 2 weeks. No wash-out	SCFAs → proliferation↑, mainly in the middle and upper thirds of the crypts	73
Radiation proctitis	7	SCFA for 4 weeks	SCFAs → clinical symptoms↓	113
	15	40 mM butyrate vs. placebo b.d. for 2 weeks. Wash-out: 1 week	No differences between groups	122
	19	130 mM SCFA (46:23:31) vs. placebo 60 mL, pH = 7 b.d. for 5 weeks	SCFAs → rectal bleeding↓, endoscopic score↓ and haemoglobin↑	117
	20	80 mM butyrate and placebo 80 mL for 3 weeks. No wash-out	Butyrate → clinical symptoms↓, endoscopic and histological scores↓	125
Pouch after UC	25	130 mM SCFA (46:23:31) 30 mL b.d. pH = 7 for 1–2 weeks	SCFAs → no effects of on defecation frequency and endoscopic and histological scores of pouches	123

\* Ratio = acetate:propionate:butyrate.

SCFA, short-chain fatty acid; CS, corticosteroid; 5-ASA, 5-aminosalicylic acid; b.d., twice daily.

after Hartmann's procedure and found trophic effects of SCFA mixtures in the mucosa of the closed rectal and sigmoid segment.<sup>73, 116</sup>

The effects of butyrate containing enemas on radiation proctitis<sup>113, 117, 122, 125</sup> and pouchitis<sup>123</sup> have been studied in small groups and besides one report<sup>125</sup> that showed that butyrate was an effective treatment of radiation proctitis, other studies did not report clear-cut beneficial effects of SCFA irrigation in these two patient groups.<sup>113, 117, 122, 123</sup>

The equivocal results in human intervention studies using enemas may partly be explained by differences in treatment duration, butyrate enemas vs. SCFA enemas, differences in concentrations and volumes of these SCFAs and the small number of patients included. Moreover, some studies suffered from methodological limitations such as a crossover design with insufficient wash-out time that may have resulted in differences in pre-treatment levels between groups (Table 1).

As there are limitations to prolonged use of rectal enemas, especially with regard to the compliance, oral ingestion of fermentable dietary fibre and the use of enteric-coated tablets containing butyrate have been explored. Administration of such tablets (4 g of butyrate daily) in combination with mesalazine vs. mesalazine alone, significantly improved the disease activity score in patients with mild-to-moderate UC.<sup>41</sup> Similar butyrate tablets also resulted in a significant clinical improvement in Crohn's disease patients, but this study lacked a control group.<sup>127</sup>

The effects of fermentable fibre supplementations, such as germinated barley foodstuff,<sup>128–130</sup> inulin,<sup>131, 132</sup> psyllium<sup>133, 134</sup> and oat bran,<sup>9</sup> which increase faecal butyrate concentrations, have also been studied in several clinical trials. Germinated barley foodstuff prolonged remission in inactive UC patients<sup>128</sup> and attenuated clinical activity in active UC patients.<sup>129, 130</sup> Inulin supplementation resulted in a decreased mucosal inflammation of the ileal reservoir in patients with an ileal-anal pouch anastomosis<sup>132</sup> and lowered faecal calprotectin concentrations in patients with active UC.<sup>131</sup> Two other studies in UC patients in remission, evaluating the supplementation of psyllium and oat bran, showed that the supplementation was safe, increased faecal butyrate concentrations and were found to be effective in the maintenance of remission.<sup>9, 133, 134</sup> However, this effectiveness should be confirmed in larger clinical trials.

Although not all studies in patients with colonic inflammation confirmed the reduction in inflammation

and clinical symptoms as a result of luminal administration of butyrate or stimulation of luminal butyrate production by the ingestion of dietary fibre, an amelioration of the inflammation and symptoms in active UC patients is strongly suggested. In addition, butyrate might play a role in the prevention of inflammation as supported by the results with UC patients in remission.

### Mechanisms of butyrate's anti-inflammatory effect

Apart from being an important energy source for the colonocytes, butyrate can exert direct immuno-modulatory effects.<sup>111, 115, 135</sup> Suppression of nuclear factor kappa B (NF- $\kappa$ B) activation, which may result from the inhibition of HDAC, is the most frequently studied anti-inflammatory effect of butyrate.<sup>136, 137</sup>

Nuclear factor- $\kappa$ B is a transcription factor that controls the expression of genes encoding proinflammatory cytokines, chemokines, inducible inflammatory enzymes such as inducible NO synthase and cyclo-oxygenase-2, adhesion molecules, growth factors, some acute phase proteins and immune receptors.<sup>138</sup> In a study with UC patients, the increased mucosal levels of activated NF- $\kappa$ B were reduced by butyrate and this correlated with a decrease in the disease activity index and the numbers of infiltrated neutrophils and lymphocytes.<sup>115</sup> This anti-inflammatory effect of butyrate via NF- $\kappa$ B inhibition, contributing, for example, to decreased concentrations of myeloperoxidase, cyclo-oxygenase-2, adhesion molecules and different cytokine levels, has been confirmed in several *in vitro* and *in vivo* studies.<sup>109, 111, 112</sup>

Apart from inhibition of NF- $\kappa$ B activation, butyrate may exert an anti-inflammatory activity through inhibition of the interferon- $\gamma$  production and/or signalling<sup>139, 140</sup> and the upregulation of peroxisome proliferator-activated receptor- $\gamma$  (PPAR $\gamma$ ).<sup>141–145</sup> PPAR $\gamma$  is a ligand-activated transcription factor that is highly expressed in colonic epithelial cells and its activation is thought to exert anti-inflammatory effects.<sup>146</sup> PPAR $\gamma$  protein expression is 60% lower in the non-inflamed colonic mucosa of UC patients compared with that in controls.<sup>147</sup> Modulation of PPAR $\gamma$  protein expression in UC may prove to be an interesting treatment for UC.

Finally, butyrate as well as other SCFAs can act as signalling molecules through specific G-protein-coupled receptors, GPR41 and GPR43, identified for SCFAs.<sup>148–150</sup> These two SCFA receptors are expressed

on immune cells, particularly polymorphonuclear leucocytes, and are also highly present in the colonic mucosa.<sup>151</sup> It has been hypothesized that these receptors play a role in the immune surveillance of the colonic mucosa towards microbial activity.<sup>149–151</sup>

In conclusion, several mechanisms for the anti-inflammatory activity of butyrate have been described, which can contribute to the observed clinical effectiveness of colonic butyrate supplementation on colonic inflammation.

## BUTYRATE AND OXIDATIVE STRESS

As described above, butyrate may influence the inflammatory process and the initiation and progression of carcinogenesis. In both these processes, oxidative stress is involved.<sup>152, 153</sup> Oxidative stress is the result of an imbalance between the generation of reactive oxygen and reactive nitrogen species and the antioxidant defence mechanisms, resulting in a cascade of reactions in which lipids, proteins and DNA may be damaged. Neutrophilic granulocytes are an important source of potent oxidizing species in the inflamed colon.<sup>152</sup>

There is some evidence that butyrate is able to modulate oxidative stress. In two studies, preincubation of isolated rat<sup>154</sup> or human<sup>155</sup> colonocytes with butyrate showed a significant reduction in H<sub>2</sub>O<sub>2</sub>-induced DNA damage. In rats, resistant starch intake decreased the levels of colonocyte DNA damage induced by a high protein diet. This DNA damage correlated negatively with caecal butyrate concentrations.<sup>156</sup>

The mechanism by which butyrate reduces oxidative stress remains unknown. Scavenger activity of butyrate is unlikely because of its chemical structure. However, butyrate may affect DNA repair systems and levels of enzymatic or non-enzymatic (anti)oxidant systems. For example, fermentable fibre supplementation resulted in a decreased colonic myeloperoxidase activity and a restoration of the colonic concentration of the antioxidant glutathione in a rat model of TNBS-induced colitis.<sup>122</sup> In addition, butyrate enhanced the activity of glutathione-S-transferase in HT-29 cells<sup>88</sup> and increased catalase activity in artery smooth muscle cells of rats.<sup>157</sup>

Although human *in vivo* data are not yet available, butyrate may enhance the protection against mucosal oxidative stress by affecting the activity of intracellular antioxidants, DNA repair systems or (anti)oxidant enzymes.

## BUTYRATE AND THE COLONIC DEFENCE BARRIER

Besides the effects of butyrate on carcinogenesis, inflammation and oxidative stress, butyrate has been shown to affect several components of the colonic defence barrier leading to enhanced protection against luminal antigens. One important component of this barrier is the mucous layer covering the epithelial lining consisting of mainly mucin glycoproteins and trefoil factors (TFFs). Mucin glycoproteins are classified into neutral and acidic subtypes and the latter category further includes sulfomucins and sialomucins. Sulphated mucins are generally considered to be more resistant to bacterial degradation.<sup>158</sup> Several epithelial mucin (MUC) genes have been identified in humans, of which MUC2 is predominantly expressed in the human colon.<sup>159</sup> Alterations in goblet cell function, composition and thickness of the intestinal mucous layer have been found in several intestinal disorders. For example, a reduced mucous thickness and a decreased MUC2 production have been reported in UC patients.<sup>160</sup>

In *in vitro* studies, butyrate increased the MUC2 gene expression in specific cell lines.<sup>161–164</sup> In addition, 0.1–1 mM butyrate administered to human colonic biopsy specimens *ex vivo* stimulated mucin synthesis.<sup>165</sup> Luminal butyrate administration of 5 mM, but not 100 mM, increased mucous secretion in an isolated perfused rat colon.<sup>166</sup> In another rat study, caecal and faecal SCFA concentrations were found to correlate with mucous thickness. In humans, effects of butyrate alone on mucous synthesis, thickness of the mucous layer and MUC expression *in vivo* have not been reported.

The effects of a number of fermentable dietary fibres on the mucous layer have been studied with varying results. For example, resistant starch increased the number of acidic mucins, but did not affect the number of goblet cells in rats.<sup>61</sup> In contrast, fructo-oligosaccharides (FOS) increased the number of goblet cells in piglets.<sup>167</sup> In a human intervention study with patients with an ileo-anal pouch, inulin supplementation did not alter MUC2 expression or the ratio between sulfomucins and sialomucins.<sup>168</sup>

Trefoil factors are mucin-associated peptides that contribute to the viscoelastic properties of the mucous layer. TFFs are thought to reduce the recruitment of inflammatory cells and to be involved in the maintenance and repair of the intestinal mucosa, although the exact mechanism for this effect is not yet known.<sup>169</sup> Intestinal trefoil factor (ITF or TFF3) is

almost exclusively secreted by the intestinal goblet cells.<sup>170</sup> In a rat TNBS model of colitis, TFF3 expression was decreased during active disease, and intracolonic administration of butyrate increased TFF3 expression.<sup>112, 171</sup> However, butyrate inhibited the expression of TFF3 in colon cancer cell lines<sup>172, 173</sup> and in colonic tissue of newborn rats.<sup>172</sup>

Other components of the colonic defence barrier that are involved in the maintenance of the colonic barrier, which may be influenced by butyrate are transglutaminase, antimicrobial peptides and heat shock proteins (HSPs).

The enzyme transglutaminase is actively involved in intestinal mucosal healing and correlates with the severity of inflammation in UC.<sup>174</sup> In a rat model of colitis, butyrate restored the colonic transglutaminase levels.<sup>62, 175</sup> Antimicrobial peptides such as cathelicidin (LL-37) and defensins, protect the gastrointestinal mucosa against the invasion and adherence of bacteria and thereby prevent infection.<sup>176–178</sup> Several *in vitro* studies have shown that butyrate upregulates the expression of LL-37 in different colon epithelial cell lines as well as in freshly isolated colorectal epithelial cells.<sup>179</sup> HSPs confer protection against inflammation by suppressing the production of inflammatory modulators.<sup>180, 181</sup> Butyrate induced the expression of HSP70 and HSP25 in Caco-2 cells<sup>181</sup> and in rats.<sup>61, 180, 182</sup> However, in a study in rats with DSS-induced colitis, butyrate inhibited HSP70 expression. This was related to protection against the decrease in cell viability, increase in mucosal permeability and neutrophil infiltration in DSS colitis. It was concluded that the induction of heat shock response has a protective effect before an injury, whereas activation of heat shock response leads to cytotoxic effects after a proinflammatory stimulus.<sup>183</sup>

In addition, there is evidence from *in vitro* studies with human colon cancer cell lines that butyrate is involved in repair after mucosal damage through an increase in the rate of cell migration. Efficient repair of superficial injuries and mucosal ulcers is important in maintaining and re-establishing the epithelial barrier.<sup>184</sup>

In conclusion, there are several lines of evidence suggesting that butyrate reinforces the colonic defence barrier by affecting several components of this barrier, such as the promotion of epithelial migration and the induction of mucins, TFF, transglutaminase activity, antimicrobial peptides and HSPs. However, most of these effects still have to be confirmed in the human situation.

## BUTYRATE AND INTESTINAL EPITHELIAL PERMEABILITY

Intestinal epithelial permeability has been widely studied as an important parameter of the intestinal defence barrier. Under normal conditions, the epithelium provides a highly selective barrier that prevents the passage of toxic and proinflammatory molecules from the external milieu into the submucosa and systemic circulation. Macromolecules pass the epithelial barrier mainly via the paracellular route for which tight junctions are the rate-limiting structures.<sup>185</sup> Increased permeability, indicating impaired epithelial barrier function, is thought to be involved in the pathophysiology of several gastrointestinal inflammatory diseases, but can either be a cause or a consequence of inflammation.<sup>186</sup>

Several studies have assessed the effects of butyrate on intestinal permeability *in vitro* as well as *ex vivo*. At low concentrations, butyrate (up to 2 mM) induces a concentration-dependent reversible decrease in permeability in a Caco-2 and HT-29 cell lines.<sup>187, 188</sup> This decrease in permeability may be related to the butyrate associated increased expression of tight junction proteins observed in different cultured cell lines, but this effect was shown to be cell type dependent.<sup>189, 190</sup> At higher concentrations (8 mM), however, butyrate increased the permeability in a Caco-2 cell line.<sup>188</sup> An *ex vivo* study, using adult rat distal colon mucosa mounted in an Ussing chamber, demonstrated that acute exposure to butyrate at a concentration of 10 mM, but not 1 or 5 mM increased paracellular permeability in rat colon.<sup>191</sup> This has also been demonstrated in rats fed a diet-containing fermentable FOS. The rapid bacterial fermentation of FOS led to accumulation of high concentrations of SCFAs that increased intestinal permeability and was associated with increased translocation of *Salmonella*.<sup>192</sup> However, in humans, daily FOS supplementation of 20 g did not increase intestinal permeability.<sup>193</sup>

It can be concluded that the effect of butyrate on intestinal permeability depends on its concentration and on the model system or species used. The effects of butyrate at different concentrations remain to be evaluated in the human *in vivo* situation.

## BUTYRATE AND SATIETY

It has been hypothesized that SCFAs produced in the large intestine also can influence upper gut motility and satiety.<sup>194</sup> Endocrine L-cells present in large

concentrations in the colonic mucosa secrete peptides such as glucagon-like peptide 1 (GLP-1), peptide YY (PYY) and oxyntomodulin, which are involved in appetite regulation.<sup>195</sup> In several animal studies using fermentable carbohydrates such as inulin,<sup>195</sup> lactitol<sup>196</sup> and FOS,<sup>197, 198</sup> an increased satiety, decreased weight gain and increased endogenous production of GLP-1 and/or PYY were reported. In humans, FOS increased satiety<sup>199</sup> and increased plasma GLP-1 concentrations.<sup>200</sup> However, lactitol did not affect plasma concentrations of this gut peptide.<sup>196</sup>

The increased satiety is possibly promoted through the production of SCFAs. This is supported by a number of studies. Butyrate increased the expression of PYY and proglucagon *in vitro* in rat epithelial cells<sup>201</sup> and increased PYY release, but not that of GLP-1, in the isolated colon of rats<sup>202, 203</sup> and rabbits.<sup>204</sup> In addition, colonic SCFA infusion in rats stimulated PYY release.<sup>205</sup> However, colonic infusion with SCFAs in humans did not increase plasma levels of either PYY or GLP-1.<sup>206</sup> Activation of the SCFA receptor GPR43 expressed in endocrine L-cells may play a role in this effect on satiety.<sup>148</sup>

There is increasing evidence that the effect of fermentable dietary fibre on satiety is mediated through the colonic production of SCFAs. However, most evidence originates from rat studies, while again human evidence remains limited.

## ADVERSE EFFECTS OF BUTYRATE

In contrast to the wide range of positive effects of butyrate on the intestinal mucosa, a small number of studies have also shown some adverse effects. Two rat studies revealed that rectal administration of butyrate (8–1000 mM), dose dependently increased colonic visceral sensitivity.<sup>207, 208</sup> However, these effects have not yet been reported in humans.

In faeces of weaning children, low butyrate concentrations have been measured.<sup>209</sup> It has been hypothesized that overproduction or accumulation of SCFAs may be toxic to the intestinal mucosa of premature infants and might play a role in the pathogenesis of neonatal necrotizing enterocolitis. It has been demonstrated that the severity of mucosal injury to butyrate, measured in newborn rats, was dose dependent and also depended on the maturation of the intestine.<sup>172, 210, 211</sup> It remains to be established whether luminal butyrate in premature infants can increase towards levels that are toxic for the intestinal mucosa.<sup>211</sup> In addition, as mentioned before, increased permeability and *Salmonella*

translocation has been found after FOS supplementation in a study with rats, which may be the result of SCFA accumulation.<sup>192</sup> However, this was not confirmed in the human situation.<sup>193</sup>

## CONCLUSIONS

Short-chain fatty acids are important end-products of microbial fermentation. Among the SCFAs produced in the human intestine, butyrate has been widely studied and has been shown to play an important role in the maintenance of colonic health. Increased butyrate production in the large intestine seems to be responsible for at least some of the protective effects of fermentable dietary fibre. However, it should be taken into account that the effects of increased butyrate production may be accompanied by other effects of dietary fibres and its fermentation, such as changes in the composition of the intestinal microbiota and increased faecal bulking.

The effects of butyrate are diverse and complex and involve several distinct mechanisms that go beyond the classical impact as an energy source for the intestinal epithelial cells. Frequently described are the effect on gene expression because of the inhibition of histone deacetylase and the suppression of NF- $\kappa$ B activation. Hence, butyrate exerts multiple effects such as the inhibition of colonic carcinogenesis, inflammation and oxidative stress, the improvement of the colonic defence barrier function and the promotion of satiety.

It should, however, be noted that also some equivocal results have been reported, which partly can be explained by the different butyrate concentrations and models used. In addition, a few animal and *in vitro* studies demonstrate negative effects at higher butyrate concentrations on permeability and visceral sensitivity of the large intestine.

In conclusion, in the last decade, several new insights into possible mechanisms and effects revealed that butyrate is a pivotal metabolite produced within the large intestine. However, these new insights are mainly based on *in vitro* data, animal models and some clinical intervention studies. More emphasis should be placed on human *in vivo* studies to elucidate the role of butyrate in health and disease.

## ACKNOWLEDGEMENTS

*Declaration of personal and funding interests:* The writing of this review was funded by TI Food and Nutrition.

## REFERENCES

- 1 Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and non-starch polysaccharides. *Physiol Rev* 2001; **81**: 1031–64.
- 2 Marteau P. Probiotics, prebiotics, synbiotics: ecological treatment for inflammatory bowel disease? *Gut* 2006; **55**: 1692–3.
- 3 Le Leu RK, Brown IL, Hu Y, *et al.* Effect of dietary resistant starch and protein on colonic fermentation and intestinal tumorigenesis in rats. *Carcinogenesis* 2007; **28**: 240–5.
- 4 Bergman EN. Energy contributions of volatile fatty acids from the gastrointestinal tract in various species. *Physiol Rev* 1990; **70**: 567–90.
- 5 Wachtershauer A, Stein J. Rationale for the luminal provision of butyrate in intestinal diseases. *Eur J Nutr* 2000; **39**: 164–71.
- 6 Cummings JH, Rombeau JL, Sakata T. *Physiological and Clinical Aspects of Short Chain Fatty Acids*. Cambridge: Cambridge University Press, 1995.
- 7 Fredstrom SB, Lampe JW, Jung HJ, *et al.* Apparent fiber digestibility and fecal short-chain fatty acid concentrations with ingestion of two types of dietary fiber. *JPEN J Parenter Enteral Nutr* 1994; **18**: 14–9.
- 8 Weaver GA, Tangel CT, Krause JA, *et al.* Acarbose enhances human colonic butyrate production. *J Nutr* 1997; **127**: 717–23.
- 9 Hallert C, Bjorck I, Nyman M, *et al.* Increasing fecal butyrate in ulcerative colitis patients by diet: controlled pilot study. *Inflamm Bowel Dis* 2003; **9**: 116–21.
- 10 Lewis SJ, Heaton KW. Increasing butyrate concentration in the distal colon by accelerating intestinal transit. *Gut* 1997; **41**: 245–51.
- 11 Gostner A, Blaut M, Schaffer V, *et al.* Effect of isomalt consumption on faecal microflora and colonic metabolism in healthy volunteers. *Br J Nutr* 2006; **95**: 40–50.
- 12 Hylla S, Gostner A, Dusel G, *et al.* Effects of resistant starch on the colon in healthy volunteers: possible implications for cancer prevention. *Am J Clin Nutr* 1998; **67**: 136–42.
- 13 Macfarlane GT, Gibson GR, Cummings JH. Comparison of fermentation reactions in different regions of the human colon. *J Appl Bacteriol* 1992; **72**: 57–64.
- 14 Cummings JH, Pomare EW, Branch WJ, *et al.* Short chain fatty acids in human large intestine, portal, hepatic and venous blood. *Gut* 1987; **28**: 1221–7.
- 15 Mitchell BL, Lawson MJ, Davies M, *et al.* Volatile fatty acids in the human intestine: studies in surgical patients. *Nutr Res* 1985; **5**: 1089–92.
- 16 Velazquez OC, Lederer HM, Rombeau JL. Butyrate and the colonocyte. Production, absorption, metabolism, and therapeutic implications. *Adv Exp Med Biol* 1997; **427**: 123–34.
- 17 Kawamata K, Hayashi H, Suzuki Y. Propionate absorption associated with bicarbonate secretion in vitro in the mouse cecum. *Pflugers Arch* 2007; **454**: 253–62.
- 18 McNeil NI, Cummings JH, James WP. Rectal absorption of short chain fatty acids in the absence of chloride. *Gut* 1979; **20**: 400–3.
- 19 Cuff M, Dyer J, Jones M, *et al.* The human colonic monocarboxylate transporter isoform 1: its potential importance to colonic tissue homeostasis. *Gastroenterology* 2005; **128**: 676–86.
- 20 Gupta N, Martin PM, Prasad PD, *et al.* SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter. *Life Sci* 2006; **78**: 2419–25.
- 21 Krishnan S, Ramakrishna BS, Binder HJ. Stimulation of sodium chloride absorption from secreting rat colon by short-chain fatty acids. *Dig Dis Sci* 1999; **44**: 1924–30.
- 22 Ramakrishna BS, Venkataraman S, Srinivasan P, *et al.* Amylase-resistant starch plus oral rehydration solution for cholera. *N Engl J Med* 2000; **342**: 308–13.
- 23 Dankert J, Zijlstra JB, Wolthers BG. Volatile fatty acids in human peripheral and portal blood: quantitative determination vacuum distillation and gas chromatography. *Clin Chim Acta* 1981; **110**: 301–7.
- 24 Matsumoto N, Riley S, Fraser D, *et al.* Butyrate modulates TGF-beta1 generation and function: potential renal benefit for Acacia(sen) SUPERGUM (gum arabic)? *Kidney Int* 2006; **69**: 257–65.
- 25 Wolever TM, Chiasson JL. Acarbose raises serum butyrate in human subjects with impaired glucose tolerance. *Br J Nutr* 2000; **84**: 57–61.
- 26 Wolever TM, Josse RG, Leiter LA, *et al.* Time of day and glucose tolerance status affect serum short-chain fatty acid concentrations in humans. *Metabolism* 1997; **46**: 805–11.
- 27 Wolever TM, Fernandes J, Rao AV. Serum acetate:propionate ratio is related to serum cholesterol in men but not women. *J Nutr* 1996; **126**: 2790–7.
- 28 Rose DJ, DeMeo MT, Keshavarzian A, *et al.* Influence of dietary fiber on inflammatory bowel disease and colon cancer: importance of fermentation pattern. *Nutr Rev* 2007; **65**: 51–62.
- 29 Nilsson U, Nyman M. Short-chain fatty acid formation in the hindgut of rats fed oligosaccharides varying in monomeric composition, degree of polymerisation and solubility. *Br J Nutr* 2005; **94**: 705–13.
- 30 Morrison DJ, Mackay WG, Edwards CA, *et al.* Butyrate production from oligofructose fermentation by the human faecal flora: what is the contribution of extracellular acetate and lactate? *Br J Nutr* 2006; **96**: 570–7.
- 31 van de Wiele T, Boon N, Possemiers S, *et al.* Inulin-type fructans of longer degree of polymerization exert more pronounced in vitro prebiotic effects. *J Appl Microbiol* 2007; **102**: 452–60.
- 32 Nordgaard I, Hove H, Clausen MR, *et al.* Colonic production of butyrate in patients with previous colonic cancer during long-term treatment with dietary fibre (*Plantago ovata* seeds). *Scand J Gastroenterol* 1996; **31**: 1011–20.
- 33 Araki Y, Fujiyama Y, Andoh A, *et al.* The dietary combination of germinated barley foodstuff plus *Clostridium butyricum* suppresses the dextran sulfate sodium-induced experimental colitis in rats. *Scand J Gastroenterol* 2000; **35**: 1060–7.
- 34 Stewart ML, Slavin JL. Molecular weight of guar gum affects short-chain fatty acid profile in model intestinal fermentation. *Mol Nutr Food Res* 2006; **50**: 971–6.
- 35 Nilsson U, Johansson M, Nilsson A, *et al.* Dietary supplementation with beta-glucan enriched oat bran increases faecal concentration of carboxylic acids in healthy subjects. *Eur J Clin Nutr* 2007; epub ahead of print.
- 36 Kameue C, Tsukahara T, Ushida K. Alteration of gene expression in the colon of colorectal cancer model rat by dietary sodium gluconate. *Biosci Biotechnol Biochem* 2006; **70**: 606–14.
- 37 Bajka BH, Topping DL, Cobiac L, *et al.* Butyrylated starch is less susceptible to

- enzymic hydrolysis and increases large-bowel butyrate more than high-amylose maize starch in the rat. *Br J Nutr* 2006; **96**: 276–82.
- 38 Tungland BC, Meyer D. Nondigestible oligo- and polysaccharides (dietary fiber): their physiology and role in human health and food. *Compr Rev Food Sci Food Saf* 2002; **3**: 90–109.
- 39 Conley BA, Egorin MJ, Tait N, *et al.* Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors. *Clin Cancer Res* 1998; **4**: 629–34.
- 40 Roda A, Simoni P, Magliulo M, *et al.* A new oral formulation for the release of sodium butyrate in the ileo-cecal region and colon. *World J Gastroenterol* 2007; **13**: 1079–84.
- 41 Vernia P, Monteleone G, Grandinetti G, *et al.* Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, double-blind, placebo-controlled pilot study. *Dig Dis Sci* 2000; **45**: 976–81.
- 42 Ibekwe VC, Liu F, Fadda HM, *et al.* An investigation into the in vivo performance variability of pH responsive polymers for ileo-colonic drug delivery using gamma scintigraphy in humans. *J Pharm Sci* 2006; **95**: 2760–6.
- 43 Ohkawara S, Furuya H, Nagashima K, *et al.* Oral administration of butyryvibrio fibrisolvens, a butyrate-producing bacterium, decreases the formation of aberrant crypt foci in the colon and rectum of mice. *J Nutr* 2005; **135**: 2878–83.
- 44 Araki Y, Andoh A, Takizawa J, *et al.* *Clostridium butyricum*, a probiotic derivative, suppresses dextran sulfate sodium-induced experimental colitis in rats. *Int J Mol Med* 2004; **13**: 577–80.
- 45 Scheppach W, Sommer H, Kirchner T, *et al.* Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. *Gastroenterology* 1992; **103**: 51–6.
- 46 Breuer RI, Soergel KH, Lashner BA, *et al.* Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial. *Gut* 1997; **40**: 485–91.
- 47 Bingham SA, Day NE, Luben R, *et al.* Dietary fibre in food and protection against colorectal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC): an observational study. *Lancet* 2003; **361**: 1496–501.
- 48 Burkitt DP. Epidemiology of cancer of the colon and rectum. *Cancer* 1971; **28**: 3–13.
- 49 Cassidy A, Bingham SA, Cummings JH. Starch intake and colorectal cancer risk: an international comparison. *Br J Cancer* 1994; **69**: 937–42.
- 50 Howe GR, Benito E, Castelletto R, *et al.* Dietary intake of fiber and decreased risk of cancers of the colon and rectum: evidence from the combined analysis of 13 case-control studies. *J Natl Cancer Inst* 1992; **84**: 1887–96.
- 51 Kim YI. AGA technical review: impact of dietary fiber on colon cancer occurrence. *Gastroenterology* 2000; **118**: 1235–57.
- 52 Park Y, Hunter DJ, Spiegelman D, *et al.* Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies. *JAMA* 2005; **294**: 2849–57.
- 53 Trock B, Lanza E, Greenwald P. Dietary fiber, vegetables, and colon cancer: critical review and meta-analyses of the epidemiologic evidence. *J Natl Cancer Inst* 1990; **82**: 650–61.
- 54 Clausen MR, Bonnen H, Mortensen PB. Colonic fermentation of dietary fibre to short chain fatty acids in patients with adenomatous polyps and colonic cancer. *Gut* 1991; **32**: 923–8.
- 55 McIntyre A, Gibson PR, Young GP. Butyrate production from dietary fibre and protection against large bowel cancer in a rat model. *Gut* 1993; **34**: 386–91.
- 56 Baron JA. Dietary fiber and colorectal cancer: an ongoing saga. *JAMA* 2005; **294**: 2904–6.
- 57 Lambert DW, Wood IS, Ellis A, *et al.* Molecular changes in the expression of human colonic nutrient transporters during the transition from normality to malignancy. *Br J Cancer* 2002; **86**: 1262–9.
- 58 Li H, Myeroff L, Smiraglia D, *et al.* SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers. *Proc Natl Acad Sci U S A* 2003; **100**: 8412–7.
- 59 Paroder V, Spencer SR, Paroder M, *et al.* Na(+)/monocarboxylate transport (SMCT) protein expression correlates with survival in colon cancer: molecular characterization of SMCT. *Proc Natl Acad Sci U S A* 2006; **103**: 7270–5.
- 60 Weaver GA, Krause JA, Miller TL, *et al.* Short chain fatty acid distributions of enema samples from a sigmoidoscopy population: an association of high acetate and low butyrate ratios with adenomatous polyps and colon cancer. *Gut* 1988; **29**: 1539–43.
- 61 Bauer-Marinovic M, Florian S, Muller-Schmehl K, *et al.* Dietary resistant starch type 3 prevents tumor induction by 1,2-dimethylhydrazine and alters proliferation, apoptosis and dedifferentiation in rat colon. *Carcinogenesis* 2006; **27**: 1849–59.
- 62 D'Argenio G, Cosenza V, Delle Cave M, *et al.* Butyrate enemas in experimental colitis and protection against large bowel cancer in a rat model. *Gastroenterology* 1996; **110**: 1727–34.
- 63 Kameue C, Tsukahara T, Yamada K, *et al.* Dietary sodium gluconate protects rats from large bowel cancer by stimulating butyrate production. *J Nutr* 2004; **134**: 940–4.
- 64 Medina V, Afonso JJ, Alvarez-Arguelles H, *et al.* Sodium butyrate inhibits carcinoma development in a 1,2-dimethylhydrazine-induced rat colon cancer. *JPN J Parenter Enteral Nutr* 1998; **22**: 14–7.
- 65 Reddy BS. Prevention of colon cancer by pre- and probiotics: evidence from laboratory studies. *Br J Nutr* 1998; **80**: S219–23.
- 66 Takahashi T, Satou M, Watanabe N, *et al.* Inhibitory effect of microfibril wheat bran on azoxymethane-induced colon carcinogenesis in CF1 mice. *Cancer Lett* 1999; **141**: 139–46.
- 67 Wong CS, Sengupta S, Tjandra JJ, *et al.* The influence of specific luminal factors on the colonic epithelium: high-dose butyrate and physical changes suppress early carcinogenic events in rats. *Dis Colon Rectum* 2005; **48**: 549–59.
- 68 Chirakkal H, Leech SH, Brookes KE, *et al.* Upregulation of BAK by butyrate in the colon is associated with increased Sp3 binding. *Oncogene* 2006; **25**: 7192–200.
- 69 Hinnebusch BF, Meng S, Wu JT, *et al.* The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. *J Nutr* 2002; **132**: 1012–7.
- 70 Comalada M, Bailon E, de Haro O, *et al.* The effects of short-chain fatty acids on colon epithelial proliferation and survival depend on the cellular phenotype. *J Cancer Res Clin Oncol* 2006; **132**: 487–97.
- 71 Hodin RA, Meng S, Archer S, *et al.* Cellular growth state differentially

- regulates enterocyte gene expression in butyrate-treated HT-29 cells. *Cell Growth Differ* 1996; 7: 647–53.
- 72 Mentschel J, Claus R. Increased butyrate formation in the pig colon by feeding raw potato starch leads to a reduction of colonocyte apoptosis and a shift to the stem cell compartment. *Metabolism* 2003; 52: 1400–5.
- 73 Mortensen FV, Langkilde NC, Joergensen JC, *et al.* Short-chain fatty acids stimulate mucosal cell proliferation in the closed human rectum after Hartmann's procedure. *Int J Colorectal Dis* 1999; 14: 150–4.
- 74 Scheppach W, Bartram P, Richter A, *et al.* Effect of short-chain fatty acids on the human colonic mucosa in vitro. *JPEN J Parenter Enteral Nutr* 1992; 16: 43–8.
- 75 Scheppach W, Weiler F. The butyrate story: old wine in new bottles? *Curr Opin Clin Nutr Metab Care* 2004; 7: 563–7.
- 76 Scalmati A, Lipkin M. Proliferation and differentiation biomarkers in colorectal mucosa and their application to chemoprevention studies. *Environ Health Perspect* 1993; 99: 169–73.
- 77 Biasco G, Paganelli GM, Miglioli M, *et al.* Rectal cell proliferation and colon cancer risk in ulcerative colitis. *Cancer Res* 1990; 50: 1156–9.
- 78 Gibson PR, Rosella O, Wilson AJ, *et al.* Colonic epithelial cell activation and the paradoxical effects of butyrate. *Carcinogenesis* 1999; 20: 539–44.
- 79 Sengupta S, Muir JG, Gibson PR. Does butyrate protect from colorectal cancer? *J Gastroenterol Hepatol* 2006; 21 (1 Pt 2): 209–18.
- 80 Daly K, Shirazi-Beechey SP. Microarray analysis of butyrate regulated genes in colonic epithelial cells. *DNA Cell Biol* 2006; 25: 49–62.
- 81 Davie JR. Inhibition of histone deacetylase activity by butyrate. *J Nutr* 2003; 133 (Suppl. 7): 2485S–93S.
- 82 Gibson PR. The intracellular target of butyrate's actions: HDAC or HDON'T? *Gut* 2000; 46: 447–8.
- 83 Dashwood RH, Myzak MC, Ho E. Dietary HDAC inhibitors: time to rethink weak ligands in cancer chemoprevention? *Carcinogenesis* 2006; 27: 344–9.
- 84 Berger DH. Plasmin/plasminogen system in colorectal cancer. *World J Surg* 2002; 26: 767–71.
- 85 Gibson PR, Rosella O, Rosella G, *et al.* Butyrate is a potent inhibitor of urokinase secretion by normal colonic epithelium in vitro. *Gastroenterology* 1994; 107: 410–9.
- 86 Mortensen FV, Jorgensen B, Christiansen HM, *et al.* Short-chain fatty acid enemas stimulate plasminogen activator inhibitor-1 after abdominal aortic graft surgery: a double-blinded, placebo-controlled study. *Thromb Res* 2000; 98: 361–6.
- 87 Gibson PR, Kiliass D, Rosella O, *et al.* Effect of topical butyrate on rectal epithelial kinetics and mucosal enzyme activities. *Clin Sci (Lond)* 1998; 94: 671–6.
- 88 Ebert MN, Klinder A, Peters WH, *et al.* Expression of glutathione S-transferases (GSTs) in human colon cells and inducibility of GSTM2 by butyrate. *Carcinogenesis* 2003; 24: 1637–44.
- 89 Andoh A, Shimada M, Araki Y, *et al.* Sodium butyrate enhances complement-mediated cell injury via down-regulation of decay-accelerating factor expression in colonic cancer cells. *Cancer Immunol Immunother* 2002; 50: 663–72.
- 90 Rodriguez-Salvador J, Armas-Pineda C, Perezpena-Diazconti M, *et al.* Effect of sodium butyrate on pro-matrix metalloproteinase-9 and -2 differential secretion in pediatric tumors and cell lines. *J Exp Clin Cancer Res* 2005; 24: 463–73.
- 91 Zeng H, Briske-Anderson M. Prolonged butyrate treatment inhibits the migration and invasion potential of HT1080 tumor cells. *J Nutr* 2005; 135: 291–5.
- 92 Zgouras D, Wachtershauser A, Frings D, *et al.* Butyrate impairs intestinal tumor cell-induced angiogenesis by inhibiting HIF-1 $\alpha$  nuclear translocation. *Biochem Biophys Res Commun* 2003; 300: 832–8.
- 93 Calder PC, Kew S. The immune system: a target for functional foods? *Br J Nutr* 2002; 88 (Suppl. 2): S165–77.
- 94 Neuman MG. Immune dysfunction in inflammatory bowel disease. *Transl Res* 2007; 149: 173–86.
- 95 Roediger WE. The starved colon – diminished mucosal nutrition, diminished absorption, and colitis. *Dis Colon Rectum* 1990; 33: 858–62.
- 96 Harig JM, Soergel KH, Komorowski RA, *et al.* Treatment of diversion colitis with short-chain-fatty acid irrigation. *N Engl J Med* 1989; 320: 23–8.
- 97 Sands BE. Inflammatory bowel disease: past, present, and future. *J Gastroenterol* 2007; 42: 16–25.
- 98 Roediger WE, Heyworth M, Willoughby P, *et al.* Luminal ions and short chain fatty acids as markers of functional activity of the mucosa in ulcerative colitis. *J Clin Pathol* 1982; 35: 323–6.
- 99 Vernia P, Gnaedinger A, Hauck W, *et al.* Organic anions and the diarrhea of inflammatory bowel disease. *Dig Dis Sci* 1988; 33: 1353–8.
- 100 Takaishi H, Matsuki T, Nakazawa A, *et al.* Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. *Int J Med Microbiol* 2007; epub ahead of print.
- 101 Den Hond E, Hiele M, Evenepoel P, *et al.* In vivo butyrate metabolism and colonic permeability in extensive ulcerative colitis. *Gastroenterology* 1998; 115: 584–90.
- 102 Kato K, Ishii Y, Mizuno S, *et al.* Usefulness of rectally administering [1-13C]-butyrate for breath test in patients with active and quiescent ulcerative colitis. *Scand J Gastroenterol* 2007; 42: 207–14.
- 103 Simpson EJ, Chapman MA, Dawson J, *et al.* In vivo measurement of colonic butyrate metabolism in patients with quiescent ulcerative colitis. *Gut* 2000; 46: 73–7.
- 104 Nancey S, Moussata D, Graber I, *et al.* Tumor necrosis factor alpha reduces butyrate oxidation in vitro in human colonic mucosa: a link from inflammatory process to mucosal damage? *Inflamm Bowel Dis* 2005; 11: 559–66.
- 105 Roediger WE, Moore J, Babidge W. Colonic sulfide in pathogenesis and treatment of ulcerative colitis. *Dig Dis Sci* 1997; 42: 1571–9.
- 106 Picton R, Eggo MC, Langman MJ, *et al.* Impaired detoxication of hydrogen sulfide in ulcerative colitis? *Dig Dis Sci* 2007; 52: 373–8.
- 107 Moore J, Babidge W, Millard S, *et al.* Colonic luminal hydrogen sulfide is not elevated in ulcerative colitis. *Dig Dis Sci* 1998; 43: 162–5.
- 108 Pitcher MC, Beatty ER, Cummings JH. The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis. *Gut* 2000; 46: 64–72.
- 109 Andoh A, Bamba T, Sasaki M. Physiological and anti-inflammatory roles of dietary fiber and butyrate in intestinal functions. *JPEN J Parenter Enteral Nutr* 1999; 23 (Suppl. 5): S70–3.
- 110 Butzner JD, Parmar R, Bell CJ, *et al.* Butyrate enema therapy stimulates

- mucosal repair in experimental colitis in the rat. *Gut* 1996; 38: 568–73.
- 111 Segain JP, Raingeard de la Bletiere D, Bourreille A, *et al.* Butyrate inhibits inflammatory responses through NF-kappaB inhibition: implications for Crohn's disease. *Gut* 2000; 47: 397–403.
  - 112 Song M, Xia B, Li J. Effects of topical treatment of sodium butyrate and 5-aminosalicylic acid on expression of trefoil factor 3, interleukin 1beta, and nuclear factor kappaB in trinitrobenzene sulphonic acid induced colitis in rats. *Postgrad Med J* 2006; 82: 130–5.
  - 113 al-Sabbagh R, Sinicrope FA, Sellin JH, *et al.* Evaluation of short-chain fatty acid enemas: treatment of radiation proctitis. *Am J Gastroenterol* 1996; 91: 1814–6.
  - 114 Guillemot F, Colombel JF, Neut C, *et al.* Treatment of diversion colitis by short-chain fatty acids. Prospective and double-blind study. *Dis Colon Rectum* 1991; 34: 861–4.
  - 115 Luhrs H, Gerke T, Muller JG, *et al.* Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis. *Scand J Gastroenterol* 2002; 37: 458–66.
  - 116 Mortensen FV, Hessov I, Birke H, *et al.* Microcirculatory and trophic effects of short chain fatty acids in the human rectum after Hartmann's procedure. *Br J Surg* 1991; 78: 1208–11.
  - 117 Pinto A, Fidalgo P, Cravo M, *et al.* Short chain fatty acids are effective in short-term treatment of chronic radiation proctitis: randomized, double-blind, controlled trial. *Dis Colon Rectum* 1999; 42: 788–95; discussion 795–6.
  - 118 Scheppach W. Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial. German-Austrian SCFA Study Group. *Dig Dis Sci* 1996; 41: 2254–9.
  - 119 Scheppach W, Muller JG, Boxberger F, *et al.* Histological changes in the colonic mucosa following irrigation with short-chain fatty acids. *Eur J Gastroenterol Hepatol* 1997; 9: 163–8.
  - 120 Senagore AJ, MacKeigan JM, Scheider M, *et al.* Short-chain fatty acid enemas: a cost-effective alternative in the treatment of nonspecific proctosigmoiditis. *Dis Colon Rectum* 1992; 35: 923–7.
  - 121 Steinhart AH, Hiruki T, Brzezinski A, *et al.* Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial. *Aliment Pharmacol Ther* 1996; 10: 729–36.
  - 122 Talley NA, Chen F, King D, *et al.* Short-chain fatty acids in the treatment of radiation proctitis: a randomized, double-blind, placebo-controlled, cross-over pilot trial. *Dis Colon Rectum* 1997; 40: 1046–50.
  - 123 Tonelli F, Dolara P, Batignani G, *et al.* Effects of short chain fatty acids on mucosal proliferation and inflammation of ileal pouches in patients with ulcerative colitis and familial polyposis. *Dis Colon Rectum* 1995; 38: 974–8.
  - 124 Vernia P, Annese V, Bresci G, *et al.* Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. *Eur J Clin Invest* 2003; 33: 244–8.
  - 125 Vernia P, Fracasso PL, Casale V, *et al.* Topical butyrate for acute radiation proctitis: randomised, crossover trial. *Lancet* 2000; 356: 1232–5.
  - 126 Vernia P, Marcheggiano A, Caprilli R, *et al.* Short-chain fatty acid topical treatment in distal ulcerative colitis. *Aliment Pharmacol Ther* 1995; 9: 309–13.
  - 127 Di Sabatino A, Morera R, Ciccocioppo R, *et al.* Oral butyrate for mildly to moderately active Crohn's disease. *Aliment Pharmacol Ther* 2005; 22: 789–94.
  - 128 Hanai H, Kanauchi O, Mitsuyama K, *et al.* Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. *Int J Mol Med* 2004; 13: 643–7.
  - 129 Kanauchi O, Mitsuyama K, Homma T, *et al.* Treatment of ulcerative colitis patients by long-term administration of germinated barley foodstuff: multicenter open trial. *Int J Mol Med* 2003; 12: 701–4.
  - 130 Kanauchi O, Suga T, Tochihiro M, *et al.* Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial. *J Gastroenterol* 2002; 37 (Suppl. 14): 67–72.
  - 131 Casellas F, Borruel N, Torrejon A, *et al.* Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin. *Aliment Pharmacol Ther* 2007; 25: 1061–7.
  - 132 Welters CF, Heineman E, Thunnissen FB, *et al.* Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. *Dis Colon Rectum* 2002; 45: 621–7.
  - 133 Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana JL, *et al.* Randomized clinical trial of *Plantago ovata* seeds (dietary fiber) as compared with mesalazine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). *Am J Gastroenterol* 1999; 94: 427–33.
  - 134 Hallert C, Kaldma M, Petersson BG. Ispaghula husk may relieve gastrointestinal symptoms in ulcerative colitis in remission. *Scand J Gastroenterol* 1991; 26: 747–50.
  - 135 Inan MS, Rasoulpour RJ, Yin L, *et al.* The luminal short-chain fatty acid butyrate modulates NF-kappaB activity in a human colonic epithelial cell line. *Gastroenterology* 2000; 118: 724–34.
  - 136 Andoh A, Fujiyama Y, Hata K, *et al.* Counter-regulatory effect of sodium butyrate on tumour necrosis factor-alpha (TNF-alpha)-induced complement C3 and factor B biosynthesis in human intestinal epithelial cells. *Clin Exp Immunol* 1999; 118: 23–9.
  - 137 Place RF, Noonan EJ, Giardina C. HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha. *Biochem Pharmacol* 2005; 70: 394–406.
  - 138 Jobin C, Sartor RB. The I kappa B/NF-kappa B system: a key determinant of mucosal inflammation and protection. *Am J Physiol Cell Physiol* 2000; 278: C451–62.
  - 139 Klampfer L, Huang J, Sasazuki T, *et al.* Inhibition of interferon gamma signaling by the short chain fatty acid butyrate. *Mol Cancer Res* 2003; 1: 855–62.
  - 140 Stempelj M, Keding M, Augenlicht L, *et al.* The essential role of the JAK/STAT1 signaling pathway in the expression of iNOS in intestinal epithelial cells and its regulation by butyrate. *J Biol Chem* 2007; 282: 9797–804.
  - 141 Kinoshita M, Suzuki Y, Saito Y. Butyrate reduces colonic paracellular permeability by enhancing PPARgamma activation. *Biochem Biophys Res Commun* 2002; 293: 827–31.
  - 142 Schwab M, Reynders V, Loitsch S, *et al.* Involvement of different nuclear hormone receptors in butyrate-mediated inhibition of inducible NF-kappaB signalling. *Mol Immunol* 2007; 44: 3625–32.

- 143 Schwab M, Reynders V, Ulrich S, *et al.* PPAR $\gamma$  is a key target of butyrate-induced caspase-3 activation in the colorectal cancer cell line Caco-2. *Apoptosis* 2006; 11: 1801–11.
- 144 Ulrich S, Wachtershauser A, Loitsch S, *et al.* Activation of PPAR $\gamma$  is not involved in butyrate-induced epithelial cell differentiation. *Exp Cell Res* 2005; 310: 196–204.
- 145 Wachtershauser A, Loitsch SM, Stein J. PPAR- $\gamma$  is selectively upregulated in Caco-2 cells by butyrate. *Biochem Biophys Res Commun* 2000; 272: 380–5.
- 146 Dubuquoy L, Rousseaux C, Thuru X, *et al.* PPAR $\gamma$  as a new therapeutic target in inflammatory bowel diseases. *Gut* 2006; 55: 1341–9.
- 147 Dubuquoy L, Jansson EA, Deeb S, *et al.* Impaired expression of peroxisome proliferator-activated receptor  $\gamma$  in ulcerative colitis. *Gastroenterology* 2003; 124: 1265–76.
- 148 Karaki SI, Tazoe H, Hayashi H, *et al.* Expression of the short-chain fatty acid receptor, GPR43, in the human colon. *J Mol Histol* 2007; epub ahead of print.
- 149 Covington DK, Briscoe CA, Brown AJ, *et al.* The G-protein-coupled receptor 40 family (GPR40-GPR43) and its role in nutrient sensing. *Biochem Soc Trans* 2006; 34 (Pt 5): 770–3.
- 150 Brown AJ, Goldsworthy SM, Barnes AA, *et al.* The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. *J Biol Chem* 2003; 278: 11312–9.
- 151 Karaki S, Mitsui R, Hayashi H, *et al.* Short-chain fatty acid receptor, GPR43, is expressed by enteroendocrine cells and mucosal mast cells in rat intestine. *Cell Tissue Res* 2006; 324: 353–60.
- 152 Rezaie A, Parker RD, Abdollahi M. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? *Dig Dis Sci* 2007; 52: 2015–21.
- 153 Skrzydlewska E, Sulkowski S, Koda M, *et al.* Lipid peroxidation and antioxidant status in colorectal cancer. *World J Gastroenterol* 2005; 11: 403–6.
- 154 Abrahamse SL, Pool-Zobel BL, Rechkemmer G. Potential of short chain fatty acids to modulate the induction of DNA damage and changes in the intracellular calcium concentration by oxidative stress in isolated rat distal colon cells. *Carcinogenesis* 1999; 20: 629–34.
- 155 Rosignoli P, Fabiani R, De Bartolomeo A, *et al.* Protective activity of butyrate on hydrogen peroxide-induced DNA damage in isolated human colonocytes and HT29 tumour cells. *Carcinogenesis* 2001; 22: 1675–80.
- 156 Toden S, Bird AR, Topping DL, *et al.* Dose-dependent reduction of dietary protein-induced colonocyte DNA damage by resistant starch in rats correlates more highly with caecal butyrate than with other short chain fatty acids. *Cancer Biol Ther* 2007; 6: 253–8.
- 157 Yano S, Tierney DF. Butyrate increases catalase activity and protects rat pulmonary artery smooth muscle cells against hyperoxia. *Biochem Biophys Res Commun* 1989; 164: 1143–8.
- 158 Deplancke B, Gaskins HR. Microbial modulation of innate defense: goblet cells and the intestinal mucus layer. *Am J Clin Nutr* 2001; 73: 1131S–41S.
- 159 Gendler SJ, Spicer AP. Epithelial mucin genes. *Annu Rev Physiol* 1995; 57: 607–34.
- 160 Einerhand AW, Renes IB, Makkink MK, *et al.* Role of mucins in inflammatory bowel disease: important lessons from experimental models. *Eur J Gastroenterol Hepatol* 2002; 14: 757–65.
- 161 Gaudier E, Jarry A, Blottiere HM, *et al.* Butyrate specifically modulates MUC gene expression in intestinal epithelial goblet cells deprived of glucose. *Am J Physiol Gastrointest Liver Physiol* 2004; 287: G1168–74.
- 162 Hatayama H, Iwashita J, Kuwajima A, *et al.* The short chain fatty acid, butyrate, stimulates MUC2 mucin production in the human colon cancer cell line, LS174T. *Biochem Biophys Res Commun* 2007; 356: 599–603.
- 163 Willemsen LE, Koetsier MA, van Deventer SJ, *et al.* Short chain fatty acids stimulate epithelial mucin 2 expression through differential effects on prostaglandin E(1) and E(2) production by intestinal myofibroblasts. *Gut* 2003; 52: 1442–7.
- 164 Augenlicht L, Shi L, Mariadason J, *et al.* Repression of MUC2 gene expression by butyrate, a physiological regulator of intestinal cell maturation. *Oncogene* 2003; 22: 4983–92.
- 165 Finnie IA, Dwarakanath AD, Taylor BA, *et al.* Colonic mucin synthesis is increased by sodium butyrate. *Gut* 1995; 36: 93–9.
- 166 Barcelo A, Claustre J, Moro F, *et al.* Mucin secretion is modulated by luminal factors in the isolated vascularly perfused rat colon. *Gut* 2000; 46: 218–24.
- 167 Tsukahara T, Iwasaki Y, Nakayama K, *et al.* Stimulation of butyrate production in the large intestine of weaning piglets by dietary fructooligosaccharides and its influence on the histological variables of the large intestinal mucosa. *J Nutr Sci Vitaminol (Tokyo)* 2003; 49: 414–21.
- 168 Meijer HP, Welters CF, Heineman E, *et al.* Enteral inulin does not affect epithelial gene expression and cell turnover within the ileoanal pouch. *Dis Colon Rectum* 2000; 43: 1427–34.
- 169 Barrett KE. A new twist on trefoils. Focus on “TFF3 modulates NF- $\kappa$ B and a novel regulatory molecule of NF- $\kappa$ B in intestinal epithelial cells via a mechanism distinct from TNF- $\alpha$ ”. *Am J Physiol Cell Physiol* 2005; 289: C1069–71.
- 170 Thim L. Trefoil peptides: from structure to function. *Cell Mol Life Sci* 1997; 53: 888–903.
- 171 Loncar MB, Al-azhah ED, Sommer PS, *et al.* Tumour necrosis factor  $\alpha$  and nuclear factor  $\kappa$ B inhibit transcription of human TFF3 encoding a gastrointestinal healing peptide. *Gut* 2003; 52: 1297–303.
- 172 Lin J, Peng L, Itzkowitz S, *et al.* Short-chain fatty acid induces intestinal mucosal injury in newborn rats and down-regulates intestinal trefoil factor gene expression in vivo and in vitro. *J Pediatr Gastroenterol Nutr* 2005; 41: 607–11.
- 173 Tran CP, Familari M, Parker LM, *et al.* Short-chain fatty acids inhibit intestinal trefoil factor gene expression in colon cancer cells. *Am J Physiol* 1998; 275 (1 Pt 1): G85–94.
- 174 D’Argenio G, Calvani M, Della Valle N, *et al.* Differential expression of multiple transglutaminases in human colon: impaired keratinocyte transglutaminase expression in ulcerative colitis. *Gut* 2005; 54: 496–502.
- 175 D’Argenio G, Cosenza V, Sorrentini I, *et al.* Butyrate, mesalamine, and factor XIII in experimental colitis in the rat: effects on transglutaminase activity. *Gastroenterology* 1994; 106: 399–404.
- 176 Kiehne K, Brunke G, Wegner F, *et al.* Defensin expression in chronic pouchitis in patients with ulcerative colitis or familial adenomatous polyposis coli. *World J Gastroenterol* 2006; 12: 1056–62.

- 177 Schaubert J, Dorschner RA, Yamasaki K, *et al.* Control of the innate epithelial antimicrobial response is cell-type specific and dependent on relevant micro-environmental stimuli. *Immunology* 2006; **118**: 509–19.
- 178 Wehkamp J, Stange EF. A new look at Crohn's disease: breakdown of the mucosal antibacterial defense. *Ann N Y Acad Sci* 2006; **1072**: 321–31.
- 179 Schaubert J, Svanholm C, Termen S, *et al.* Expression of the cathelicidin LL-37 is modulated by short chain fatty acids in colonocytes: relevance of signalling pathways. *Gut* 2003; **52**: 735–41.
- 180 Arvans DL, Vavricka SR, Ren H, *et al.* Luminal bacterial flora determines physiological expression of intestinal epithelial cytoprotective heat shock proteins 25 and 72. *Am J Physiol Gastrointest Liver Physiol* 2005; **288**: G696–704.
- 181 Malago JJ, Koninkx JF, Tooten PC, *et al.* Anti-inflammatory properties of heat shock protein 70 and butyrate on *Salmonella*-induced interleukin-8 secretion in enterocyte-like Caco-2 cells. *Clin Exp Immunol* 2005; **141**: 62–71.
- 182 Ren H, Musch MW, Kojima K, *et al.* Short-chain fatty acids induce intestinal epithelial heat shock protein 25 expression in rats and IEC 18 cells. *Gastroenterology* 2001; **121**: 631–9.
- 183 Venkatraman A, Ramakrishna BS, Shaji RV, *et al.* Amelioration of dextran sulfate colitis by butyrate: role of heat shock protein 70 and NF-kappaB. *Am J Physiol Gastrointest Liver Physiol* 2003; **285**: G177–84.
- 184 Wilson AJ, Gibson PR. Short-chain fatty acids promote the migration of colonic epithelial cells in vitro. *Gastroenterology* 1997; **113**: 487–96.
- 185 Walsh SV, Hopkins AM, Nusrat A. Modulation of tight junction structure and function by cytokines. *Adv Drug Deliv Rev* 2000; **41**: 303–13.
- 186 Poritz LS, Garver KI, Green C, *et al.* Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. *J Surg Res* 2007; **140**: 12–9.
- 187 Mariadason JM, Barkla DH, Gibson PR. Effect of short-chain fatty acids on paracellular permeability in Caco-2 intestinal epithelium model. *Am J Physiol* 1997; **272** (4 Pt 1): G705–12.
- 188 Peng L, He Z, Chen W, *et al.* Effects of butyrate on intestinal barrier function in a caco-2 cell monolayer model of intestinal barrier. *Pediatr Res* 2007; **61**: 37–41.
- 189 Bordin M, D'Atri F, Guillemot L, *et al.* Histone deacetylase inhibitors up-regulate the expression of tight junction proteins. *Mol Cancer Res* 2004; **2**: 692–701.
- 190 Ohata A, Usami M, Miyoshi M. Short-chain fatty acids alter tight junction permeability in intestinal monolayer cells via lipoxygenase activation. *Nutrition* 2005; **21**: 838–47.
- 191 Mariadason JM, Kilias D, Catto-Smith A, *et al.* Effect of butyrate on paracellular permeability in rat distal colonic mucosa ex vivo. *J Gastroenterol Hepatol* 1999; **14**: 873–9.
- 192 Ten Bruggencate SJ, Bovee-Oudenhoven IM, Lettink-Wissink ML, *et al.* Dietary fructooligosaccharides increase intestinal permeability in rats. *J Nutr* 2005; **135**: 837–42.
- 193 Ten Bruggencate SJ, Bovee-Oudenhoven IM, Lettink-Wissink ML, *et al.* Dietary fructooligosaccharides affect intestinal barrier function in healthy men. *J Nutr* 2006; **136**: 70–4.
- 194 Cherbut C. Motor effects of short-chain fatty acids and lactate in the gastrointestinal tract. *Proc Nutr Soc* 2003; **62**: 95–9.
- 195 Delzenne NM, Cani PD, Daubioul C, *et al.* Impact of inulin and oligofructose on gastrointestinal peptides. *Br J Nutr* 2005; **93** (Suppl. 1): S157–61.
- 196 Gee JM, Johnson IT. Dietary lactitol fermentation increases circulating peptide YY and glucagon-like peptide-1 in rats and humans. *Nutrition* 2005; **21**: 1036–43.
- 197 Cani PD, Neyrinck AM, Maton N, *et al.* Oligofructose promotes satiety in rats fed a high-fat diet: involvement of glucagon-like peptide-1. *Obes Res* 2005; **13**: 1000–7.
- 198 Delmee E, Cani PD, Gual G, *et al.* Relation between colonic proglucagon expression and metabolic response to oligofructose in high fat diet-fed mice. *Life Sci* 2006; **79**: 1007–13.
- 199 Cani PD, Joly E, Horsmans Y, *et al.* Oligofructose promotes satiety in healthy human: a pilot study. *Eur J Clin Nutr* 2006; **60**: 567–72.
- 200 Piche T, des Varannes SB, Sacher-Huvelin S, *et al.* Colonic fermentation influences lower esophageal sphincter function in gastroesophageal reflux disease. *Gastroenterology* 2003; **124**: 894–902.
- 201 Zhou J, Hegsted M, McCutcheon KL, *et al.* Peptide YY and proglucagon mRNA expression patterns and regulation in the gut. *Obesity (Silver Spring)* 2006; **14**: 683–9.
- 202 Plaisancie P, Dumoulin V, Chayvialle JA, *et al.* Luminal peptide YY-releasing factors in the isolated vascularly perfused rat colon. *J Endocrinol* 1996; **151**: 421–9.
- 203 Plaisancie P, Dumoulin V, Chayvialle JA, *et al.* Luminal glucagon-like peptide-1(7-36) amide-releasing factors in the isolated vascularly perfused rat colon. *J Endocrinol* 1995; **145**: 521–6.
- 204 Longo WE, Ballantyne GH, Savoca PE, *et al.* Short-chain fatty acid release of peptide YY in the isolated rabbit distal colon. *Scand J Gastroenterol* 1991; **26**: 442–8.
- 205 Cherbut C, Ferrier L, Roze C, *et al.* Short-chain fatty acids modify colonic motility through nerves and polypeptide YY release in the rat. *Am J Physiol* 1998; **275** (6 Pt 1): G1415–22.
- 206 Ropert A, Cherbut C, Roze C, *et al.* Colonic fermentation and proximal gastric tone in humans. *Gastroenterology* 1996; **111**: 289–96.
- 207 Bourdu S, Dapoigny M, Chapuy E, *et al.* Rectal instillation of butyrate provides a novel clinically relevant model of noninflammatory colonic hypersensitivity in rats. *Gastroenterology* 2005; **128**: 1996–2008.
- 208 Tarrerias AL, Millecamps M, Alloui A, *et al.* Short-chain fatty acid enemas fail to decrease colonic hypersensitivity and inflammation in TNBS-induced colonic inflammation in rats. *Pain* 2002; **100**: 91–7.
- 209 Scheiwiller J, Arrigoni E, Brouns F, *et al.* Human faecal microbiota develops the ability to degrade type 3 resistant starch during weaning. *J Pediatr Gastroenterol Nutr* 2006; **43**: 584–91.
- 210 Lin J, Nafday SM, Chauvin SN, *et al.* Variable effects of short chain fatty acids and lactic acid in inducing intestinal mucosal injury in newborn rats. *J Pediatr Gastroenterol Nutr* 2002; **35**: 545–50.
- 211 Nafday SM, Chen W, Peng L, *et al.* Short-chain fatty acids induce colonic mucosal injury in rats with various postnatal ages. *Pediatr Res* 2005; **57**: 201–4.